Mostrar el registro sencillo del ítem
dc.contributor.author | Vicent, Lourdes | |
dc.contributor.author | Ayesta, Ana | |
dc.contributor.author | Esteban Fernández, Alberto | |
dc.contributor.author | Gómez Bueno, Manuel | |
dc.contributor.author | Juan Bagudá, Javier de | |
dc.contributor.author | Díez Villanueva, Pablo | |
dc.contributor.author | Iniesta, Ángel Manuel | |
dc.contributor.author | Rojas González, Antonio | |
dc.contributor.author | Perea Egido, Jesus Ángel | |
dc.contributor.author | Martínez Sellés Oliveria Soares, Manuel | |
dc.contributor.author | Et al. | |
dc.date.accessioned | 2019-06-17T06:38:27Z | |
dc.date.available | 2019-06-17T06:38:27Z | |
dc.date.issued | 2019 | |
dc.identifier.citation | Vicent, L., Ayesta, A., Esteban-Fernández, A., Gómez-Bueno, M., De-Juan, J., Díez-Villanueva, P., ... & Martínez-Sellés, M. (2019). Sex Influence on the Efficacy and Safety of Sacubitril/Valsartan. Cardiology, 142(2), 73-78. https://doi.org/10.1159/000498984 | spa |
dc.identifier.issn | 0008-6312 | |
dc.identifier.issn | 1421-9751 | |
dc.identifier.uri | http://hdl.handle.net/11268/8045 | |
dc.description.abstract | BACKGROUND: Women are underrepresented in sacubitril/valsartan (SV) clinical trials. The aim of this study was to assess sex-specific differences in efficacy, tolerability, and safety of SV in real-world heart failure with reduced ejection fraction (HFrEF) patients. METHODS: A prospective registry in 10 centers including all patients who started SV during the last 6 months was analyzed in this study. RESULTS: A total of 427 patients were included, 126 (29.5%) were women. There were no substantial differences in HFrEF treatment before SV initiation, although fewer women than men carried an implantable cardioverter defibrillator (57 [45.2%] vs. 173 [58.1%], p = 0.02). SV starting dose was 24/26 mg b.i.d. in 206 patients (48.2%), 49/51 mg b.i.d. in 184 (43.1%), and 97/103 mg b.i.d. in 34 (8.2%), without relevant differences associated to sex. There were no losses during a mean follow-up of 7.0 ± 0.1 months. The proportion of patients who discontinued the drug (16 [12.7%] women vs. 33 [11.0%] men, p = 0.66) or presented SV-related adverse effects (31 [24.6%] women vs. 79 [26.5%] men, p = 0.72) was also similar in both sexes. However, female sex was an independent predictor of functional class improvement in the multivariate analysis (odds ratio 2.33, 95% confidence interval: 1.24-4.38, p = 0.04). CONCLUSIONS: SV in women with HFrEF has a similar tolerability as in men. Females seem to have a more frequent functional class improvement than males. | spa |
dc.description.sponsorship | Sin financiación | spa |
dc.language.iso | eng | spa |
dc.title | Sex Influence on the Efficacy and Safety of Sacubitril/Valsartan | spa |
dc.type | article | spa |
dc.description.impact | 1.791 JCR (2019) Q3, 93/138 Cardiac & Cardiovascular Systems | spa |
dc.description.impact | 0.559 SJR (2019) Q2, 166/362 Cardiology and Cardiovascular Medicine, 125/263 Pharmacology (medical) | spa |
dc.description.impact | No data IDR 2019 | spa |
dc.identifier.doi | 10.1159/000498984 | |
dc.rights.accessRights | closedAccess | spa |
dc.subject.uem | Farmacología cardiovascular | spa |
dc.subject.uem | Diferencias entre los sexos | spa |
dc.subject.unesco | Farmacología | spa |
dc.subject.unesco | Enfermedad cardiovascular | spa |
dc.description.filiation | UEM | spa |
dc.peerreviewed | Si | spa |
Ficheros | Tamaño | Formato | Ver |
---|---|---|---|
No hay ficheros asociados a este ítem. |